mRNA vaccines manufacturing: Challenges and bottlenecks
نویسندگان
چکیده
منابع مشابه
Regulatory and Biosafety Challenges for Vaccines
The global regulatory plan for vaccines provides a unique opportunity to develop safe and effective ones with assured quality. Methods used by regulators address challenges of new products and technologies and also increase understanding of benefits and risks of existing products. First, the laboratory-based regulatory sciences evolve correlates of immunity and safety; or improve the product ch...
متن کاملDNA vaccines: progress and challenges.
In the years following the publication of the initial in vivo demonstration of the ability of plasmid DNA to generate protective immune responses, DNA vaccines have entered into a variety of human clinical trials for vaccines against various infectious diseases and for therapies against cancer, and are in development for therapies against autoimmune diseases and allergy. They also have become a...
متن کاملClustered bottlenecks in mRNA translation and protein synthesis.
Using a model based on the totally asymmetric exclusion process, we investigate the effects of slow codons along messenger RNA. Ribosome density profiles near neighboring clusters of slow codons interact, enhancing suppression of ribosome throughput when such bottlenecks are closely spaced. Increasing the slow codon cluster size beyond approximately 3-4 codons does not significantly reduce the ...
متن کاملChallenges in Sustainable Manufacturing
Since the release of Brundtland Report in 1987, sustainability practices have received a fair share of attention from researchers and practitioners alike. Sustainable manufacturing practices seek to optimize production efficiency while minimizing environmental impact and maintaining social equity. Research has shown that companies that adopt sustainable practices are able to achieve increased p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Vaccine
سال: 2021
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2021.03.038